Exclusion Criteria

- a concurrent medical condition(s) that would prevent compliance or participation or jeopardize the health of the patient
- hypersensitivity to any component of the formulation
- active severe infection/inflammation
- History of erythropoietin, >500 mg intravenous iron administration within 4 weeks prior to screening.
- History of acquired iron overload.
- Anemia due to reasons other than iron deficiency, pregnancy, or lactation.
- Decreased renal function (defined as creatinine clearance <30 mL/min calculated by Cockcroft-Gault)

7g/dl ≤ Hb<10g/dl at 5 – 7 days after gastrectomy for gastric cancer

Informed consent

Enrollment

Randomization

Placebo: IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL, as infusion or 20mL as bolus injection) for body weight = or >50Kg or 6 minutes (100mL, normal as infusion or 10mL as bolus injection) for body weight <50 Kg.

Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (for 1000mg single administration) for body weight = or >50 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg.

Follow Up at postoperative Week3: Routine examination, assessment of serum ferritin, transferrin saturation (TSAT), Hb, WBC, RBC, Platelets and blood chemistry including AST, ALT, CRP, assessment of QoL by, EORTC QLQ C-30 and Sto-22.

Follow Up at postoperative Week 12: Routine examination, assessment of serum ferritin, transferrin saturation (TSAT), Hb, WBC, RBC, Platelets and blood chemistry including AST, ALT, CRP, assessment of QoL by, EORTC QLQ C-30 and Sto-22.